FREE WEBINAR: Obstructive sleep apnoea (OSA) and obesity are tightly linked, sharing overlapping metabolic and mechanical pathways that worsen cardiometabolic risk.
With the emergence of incretin-based therapies (GLP-1 and dual GIP/GLP-1 agonists) showing substantial weight loss and reductions in apnoea severity, the treatment landscape for OSA is shifting.
This talk will cover the pathophysiological links between obesity and OSA, summarise recent clinical trial evidence for incretin therapies in OSA management, and discuss practical implications, including patient selection, referral pathways, and how these therapies may complement or reduce reliance on CPAP.
Aimed at equipping clinicians to recognise and appropriately manage patients with comorbid obesity and OSA in primary care.
As always, we will answer as many questions as possible.
Presenter
Brendon Yee
Professor Brendon Yee is a Professor of Respiratory and Sleep Medicine at Royal Prince Alfred Hospital, Head of the Discipline of Sleep Medicine at the University of Sydney, and a senior researcher at the Woolcock Institute of Medical Research. Honorary Professor at Macquarie University.
His research focuses on the links between obesity, metabolic syndrome, and obstructive sleep apnoea, with broader expertise spanning OSA phenotyping and emerging pharmacotherapies for sleep-disordered breathing.
He completed his PhD on the intersection of obesity, metabolic syndrome, and sleep apnoea, and has been involved in recent clinical trial work on incretin-based therapies for OSA.
Supported by an unrestricted educational grant from:
